Compare Remitly Global Inc (RELY) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Remitly Global Inc vs BIO-TECHNE Corp — how do they compare? Remitly Global Inc trades at $24.1 (market cap $5.26B), while BIO-TECHNE Corp trades at $72.39 (market cap $11.34B). The key difference: BIO-TECHNE Corp is far larger — about 2.2× Remitly Global Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Remitly Global Inc pays none. Which is the better fit depends on your goals.
| RELY | TECH | |
|---|---|---|
Market Cap | $5.26B | $11.34B |
Sector | Technology | Health |
52-Week High | $26.92 | $72.48 |
52-Week Low | $12.20 | $43.31 |
Enterprise Value | $4.62B | $11.36B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RELY trades at $24.83, down 5.12% over 24 hours, with a bearish technical signal but strong fundamentals. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $0.93 significantly exceeding expectations of $0.12. Revenue growth is accelerating, reaching $1.64 billion in 2025, with net income turning positive at $67.93 million. A recent partnership with Etsy expands its payment provider reach, signaling business expansion. Analyst consensus is overwhelmingly bullish with a $31.17 price target, representing 25.5% upside from current levels.
The outlook for RELY is positive given its strong revenue trajectory, improving profitability, and strategic partnerships. Key opportunities include continued market share gains in digital remittances and new monetization avenues. Risks involve competitive pressures in fintech, reliance on economic conditions affecting remittance volumes, and potential volatility despite institutional backing. The stock's current pullback may offer a entry point, but investors should weigh execution risks against growth potential.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
